Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The comp...
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-Rez
GARDEN BIOPHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 234 million yuan, a decrease of 3.07%
Zhejiang Garden Biopharma has completed the sale of shares under its 2022 employee stock ownership plan and will terminate it
GARDEN BIOPHARMA: Subsidiary obtains drug registration certificate
The price of Vitamin D3 has shown a continuous upward trend
Garden Biopharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%